VistaGen Therapeutics, Inc. (VSTA) Receives Notice of Allowance for Stem Cell Technology
Today before the opening bell, VistaGen Therapeutics announced its reception of a Notice of Allowance from the Canadian Intellectual Property Office. The Notice of Allowance enables further expansion of VistaGen Therapeutics’ intellectual property portfolio, which consists of pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells. The notice pertains to Canadian Patent Application No. 2,487,058, which is exclusively licensed to VistaGen Therapeutics by the Icahn School of Medicine at Mt. Sinai in New York and entitled “Mesoderm and Definitive Endoderm Cell Populations”. This new development builds on VistaGen…